You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Investigation of a sorbent-based potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine

    SBC: CYTOSORBENTS MEDICAL INC            Topic: DHP16010

    Hyperkalemia will clearly continue to be a concern in the treatment of combat casualties. The risk of death from hyperkalemia-induced cardiac arrhythmias is significant in the absence of renal replacement therapy (RRT). Rapid evacuation out of Iraq and Afghanistan ensured that most hyperkalemia occurred further up the evacuation chain, thereby limiting the need for non-RRT hyperkalemia treatment o ...

    SBIR Phase II 2017 Department of DefenseDefense Health Agency
  2. Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue

    SBC: MONTANA MOLECULAR LLC            Topic: 105

    Project SummaryMontana Molecular is in the business of developing and marketing genetically encoded biosensors for academic research and drug discovery in living cellsOur biosensors provide robust detection of crucial second messenger signalingincluding DAGPIPcAMP and Caon both fluorescence microscopes and the large installed base of automated plate readerswith metrics that match or surpass those ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma

    SBC: Soligenix, Inc            Topic: 102

    Project Summary Abstractchanges are in Time New Roman fontCutaneous T cell lymphomaCTCLis a rare form of Non Hodgkin s LymphomaNHLaffecting approximatelypatients annually in the United States and can be characterized by either an indolent or aggressive disease progressionEither case is accompanied by significant morbidityparticularly due to the skin effects of the diseaseThe indolent disease may e ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

    SBC: Soligenix, Inc            Topic: NIDCR

    Project Summary Abstract This proposal supports the conduct of the clinical study IDR OMentitledA PivotalDouble BlindRandomizedPlacebo ControlledMultinational Study of SGXDusquetidefor the Attenuation of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and NeckThis trial is designed to confirm the positive findings se ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Energy-Harvesting Mesofluidic Impulse Prosthesis: e-MIP

    SBC: ORTHOCARE INNOVATIONS LLC            Topic: NICHD

    PROJECT SUMMARY Power absorption and generation at the ankle is critical to gait efficiencyjoint healthresidual limb healthand safety in individuals with limb lossRecent research and commercial efforts have resulted in powered foot ankle systemswhich provide powered plantarflexion electromechanicallyreduce metabolic costs of walkingand show reductions in pathological loading of the contralateral l ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Open Speech Signal Processing Platform

    SBC: SensorLogic, Inc.            Topic: NIDCD

    This proposal will create an open speech signal processing platform. The open computational framework will be used for developing algorithms that will help accelerate acoustic and hearing science research. It will permit researchers to more rapidly and easily test new algorithms with greater control, performance, and ease. Several example systems will be created to show that the platform can be ad ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a TRPA Antagonist Opioid Sparing Analgesic for Chronic Pain

    SBC: ALGOMEDIX, INC.            Topic: NIDA

    Chronic pain affects over million Americans While opioids are recognized as the most effective drugs for the relief of pain the US is now suffering from an epidemic of abuse addiction and accidental overdose deaths resulting from prescription opioids The goal of this proposal is develop a novel non opioid analgesic drug devoid of addiction and abuse liabilities and to define its opioid spa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Kinetic Phenotype Discovery Informatics for Neurological Diseases

    SBC: DRVISION TECHNOLOGIES LLC            Topic: 101

    Project Summary Neurological disorders significantly outnumber diseases in other therapeutic areas and are growing in incidence faster than any other disease classesHoweverthe pharmaceutical industry has been unsuccessful in coming up with effective drugsA big factor in these failures has been a lack of adequate model systems for fundamental disease understanding affecting both diagnosis and treat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A high-throughput sample preparation platform for genomic and epigenetic analysis

    SBC: MATCHSTICK TECHNOLOGIES INC            Topic: 400

    Several types of cancerse gpancreatic and brain malignanciesremain extremely lethal despite the introduction of chemotherapy more thanyears agoThe hallmark of all cancers are somatic mutations which cannot be correctedIn sharp contrastepigenetic changesessential contributors to tumorigenesisare pharmacologically reversibleThe ability to remedy detrimental epigenetic alterations are opening up new ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government